Research programme: cytotoxic conjugates of disorazoles - COSCIENS Biopharma
Alternative Names: AEZS-125; AEZS-137; AEZS-138; Disorazol; Disorazol A; Disorazol A1; Disorazol E; Disorazol E1; Disorazol Z; Disorazol Z-D-Lys6-LHRH conjugate; LHRH-disorazol ZLatest Information Update: 08 Aug 2024
At a glance
- Originator GBF
- Developer COSCIENS Biopharma; Helmholtz Centre for Infection Research GmbH
- Class Drug conjugates; Macrolides; Oxazoles
- Mechanism of Action Apoptosis stimulants; LHRH receptor modulators; Mitosis inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 06 Aug 2024 AEterna Zentaris Inc is now called COSCIENS Biopharma
- 04 Nov 2017 No recent reports of development identified for preclinical development in Solid-tumours in Germany (Parenteral)
- 13 Jan 2016 AEterna Zentaris has patent protection for disorazol Z and the LHRH receptor antagonist in 15 countries